Skip to main content
. 2021 Apr 5;73(5):1795–1803. doi: 10.1007/s13304-021-01044-0

Table 2.

Pre-operative CRT regimens

Chemotherapic agent No. (%)
Capecitabine 474 (68.8%)
Folfox 32 (4.6%)
5-FU 30 (4.3%)
Folfiri + panitumumab 2 (0.3%)
Folfox + bevacizumab 2 (0.3%)
Folfoxiri 2 (0.3%)
Oxaliplatino 2 (0.3%)
5-FU + levofolinile 1 (0.15%)
Docetaxel 1 (0.15%)
Folfiri 1 (0.15%)
Folfirinox 1 (0.15%)
Atezolizumab 1 (0.15%)
Capox + bevacizumab 1 (0.15%)
Missing data 139 (20.2%)